Brent crude oil is approaching the psychologically important $100-a-barrel level, as the escalating conflict in the Middle East amplified fears of supply disruptions in the region.

The population of Japanese sardines is decreasing rapidly in the Pacific Ocean, according to a study conducted by the Japan Fisheries Research and Education Agency (FRA).

Shares of Excelland Robotics soared on their first trading day, joining a wave of companies that have made Hong Kong the world's busiest venue for public offerings. The stock was last 172% higher at ...

Demand for transportation services for induced pluripotent stem (iPS) cells is growing in Japan, a trend bolstered by advancements now being made in research on medical applications of iPS cells.

Hanwha Ocean has been selected for a roughly $510 million project to build a next-generation frigate for the Royal Thai Navy, strengthening its position in the growing Southeast Asian naval market.

Tokio Marine Holdings Inc., which formed a capital and business alliance with Berkshire Hathaway earlier this year, intends to "jointly pursue large-scale merger and acquisition (M&A) deals" with the ...

Oil prices rose early in Asian trade Wednesday as the escalating conflict in the Middle East amplified fears of supply disruptions in the region.

Lin BioScience Inc. Annual balance sheet by MarketWatch. View all 6696 assets, cash, debt, liabilities, shareholder equity and investments.

Chime Financial lifted its full-year outlook and said it agreed to acquire Stride Bank for $590 million. The stock jumped 9.4% to $35.35 after Tuesday's bell. ServiceTitan guided for third-quarter ...

S&P Dow Jones Indices has reclassified Poland as a developed economy, which is an upgrade for the country as the data provider had previously rated it as an emerging market. This has implications for ...

Trimble has acquired Terasat Japan, a virtual reference station service provider whose addition it said would give it boost its presence in Japan, the company said Tuesday. Financial terms of the deal ...

Evommune said its Phase 2b trial of a treatment for people with atopic dermatitis failed to meet its primary and secondary endpoints. The stock dropped 32%, to $8.95, in after-hours trading Tuesday.